These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35104370)

  • 1. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
    Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
    Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
    Takai K
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
    Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
    Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
    Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
    Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
    Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
    J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International definition of iMCD-TAFRO: future perspectives.
    Nishimura Y; Nishimura MF; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome.
    Sumiyoshi R; Koga T; Kawakami A
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
    Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
    Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
    Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
    Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H; Van Rhee F; Lim MS; Fajgenbaum DC
    Haematologica; 2024 Jul; 109(7):2196-2206. PubMed ID: 38205523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
    Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.